Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis.
Accessory hepatic vein
Budd-Chiari syndrome
Meta-analysis
Recanalization
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
02 Oct 2023
02 Oct 2023
Historique:
received:
23
12
2022
accepted:
21
09
2023
medline:
4
10
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Budd-Chiari syndrome (BCS) results when the outflow of the hepatic vein (HV) is obstructed. BCS patients exhibiting an accessory HV (AHV) that is dilated but obstructed can achieve significant alleviation of liver congestion after undergoing AHV recanalization. This meta-analysis was developed to explore the clinical efficacy of AHV recanalization in patients with BCS. PubMed, Embase, and Wanfang databases were searched for relevant studies published as of November 2022, and RevMan 5.3 and Stata 12.0 were used for pooled endpoint analyses. Twelve total studies were identified for analysis. Pooled primary clinical success, re-stenosis, 1- and 5-year primary patency, 1- and 5-year secondary patency, 1-year overall survival (OS), and 5-year OS rates of patients in these studies following AHV recanalization were 96%, 17%, 91%, 75%, 98%, 91%, 97%, and 96%, respectively. Patients also exhibited a significant reduction in AHV pressure after recanalization relative to preoperative levels (P < 0.00001). Endpoints exhibiting significant heterogeneity among these studies included, AHV pressure (I The present meta-analysis highlights AHV recanalization as an effective means of achieving positive long-term outcomes in patients affected by BCS, potentially achieving better long-term results than those associated with HV recanalization.
Sections du résumé
BACKGROUND
BACKGROUND
Budd-Chiari syndrome (BCS) results when the outflow of the hepatic vein (HV) is obstructed. BCS patients exhibiting an accessory HV (AHV) that is dilated but obstructed can achieve significant alleviation of liver congestion after undergoing AHV recanalization. This meta-analysis was developed to explore the clinical efficacy of AHV recanalization in patients with BCS.
MATERIALS AND METHODS
METHODS
PubMed, Embase, and Wanfang databases were searched for relevant studies published as of November 2022, and RevMan 5.3 and Stata 12.0 were used for pooled endpoint analyses.
RESULTS
RESULTS
Twelve total studies were identified for analysis. Pooled primary clinical success, re-stenosis, 1- and 5-year primary patency, 1- and 5-year secondary patency, 1-year overall survival (OS), and 5-year OS rates of patients in these studies following AHV recanalization were 96%, 17%, 91%, 75%, 98%, 91%, 97%, and 96%, respectively. Patients also exhibited a significant reduction in AHV pressure after recanalization relative to preoperative levels (P < 0.00001). Endpoints exhibiting significant heterogeneity among these studies included, AHV pressure (I
CONCLUSIONS
CONCLUSIONS
The present meta-analysis highlights AHV recanalization as an effective means of achieving positive long-term outcomes in patients affected by BCS, potentially achieving better long-term results than those associated with HV recanalization.
Identifiants
pubmed: 37784064
doi: 10.1186/s12876-023-02969-z
pii: 10.1186/s12876-023-02969-z
pmc: PMC10546748
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
340Subventions
Organisme : Natural science research in colleges and universities of Jiangsu Province
ID : 21KJD320001
Organisme : Xuzhou Key R&D Plan
ID : KC20111
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Sharma A, Keshava SN, Eapen A, et al. An Update on the Management of Budd-Chiari Syndrome. Dig Dis Sci. 2021;66:1780–90.
doi: 10.1007/s10620-020-06485-y
pubmed: 32691382
Haque LYK, Lim JK. Budd-Chiari syndrome: an uncommon cause of chronic liver disease that cannot be missed. Clin Liver Dis. 2020;24:453–81.
doi: 10.1016/j.cld.2020.04.012
pubmed: 32620283
Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2021;15:531–67.
doi: 10.1007/s12072-021-10189-4
pubmed: 34240318
Li T, Zhai S, Pang Z, et al. Feasibility and midterm outcomes of percutaneous transhepatic balloon angioplasty for symptomatic Budd-Chiari syndrome secondary to hepatic venous obstruction. J Vasc Surg. 2009;50:1079–84.
doi: 10.1016/j.jvs.2009.06.049
pubmed: 19703746
Ding PX, Zhang SJ, Li Z, et al. Long-term safety and outcome of percutaneous transhepatic venous balloon angioplasty for Budd-Chiari syndrome. J Gastroenterol Hepatol. 2016;31:222–8.
doi: 10.1111/jgh.13025
pubmed: 26102208
Bi Y, Chen H, Ding P, et al. Excellent long-term outcomes of endovascular treatment in budd-chiari syndrome with hepatic veins involvement: A STROBE-compliant article. Medicine (Baltimore). 2018;97:e12944.
doi: 10.1097/MD.0000000000012944
pubmed: 30412110
Sonavane AD, Amarapurkar DN, Rathod KR, et al. Long term survival of patients undergoing TIPS in Budd-Chiari syndrome. J Clin Exp Hepatol. 2019;9:56–61.
doi: 10.1016/j.jceh.2018.02.008
pubmed: 30765940
Inchingolo R, Posa A, Mariappan M, et al. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: A comprehensive review. World J Gastroenterol. 2020;26:5060–73.
doi: 10.3748/wjg.v26.i34.5060
pubmed: 32982109
pmcid: 7495032
Mancuso A. TIPS for Budd-Chiari syndrome: time to anticipate treatment. Liver Int. 2014;34:e325.
doi: 10.1111/liv.12544
pubmed: 24650135
Tang W, Zhang XM, Yang L, et al. Hepatic caudate vein in Budd-Chiari syndrome: depiction by using magnetic resonance imaging. Eur J Radiol. 2011;77:143–8.
doi: 10.1016/j.ejrad.2009.06.026
pubmed: 19631484
Chen ZK, Fan J, Cao C, et al. Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome. Radiol Med. 2018;123:799–807.
doi: 10.1007/s11547-018-0907-2
pubmed: 29856000
Cui YF, Fu YF, Li DC, et al. Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival. Hepatol Int. 2016;10:363–9.
doi: 10.1007/s12072-015-9676-3
pubmed: 26497183
Fu Y, Zhang K, Wei N, et al. Significance of an accessory hepatic vein in the interventional treatment of Budd-Chiari syndrome. Chin J Hepatobiliary Surg. 2014;20:346–50.
Fu YF, Xu H, Zhang K, et al. Accessory hepatic vein recanalization for treatment of Budd-Chiari syndrome due to long-segment obstruction of the hepatic vein: initial clinical experience. Diagn Interv Radiol. 2015;21:148–53.
doi: 10.5152/dir.2014.14128
pubmed: 25616271
pmcid: 4463317
Li DM, Yin X, Yang F, et al. Accessory hepatic vein recanalization for hepatic vein-type Budd-Chiari syndrome. Minim Invasive Ther Allied Technol. 2021;30:239–44.
doi: 10.1080/13645706.2020.1723110
pubmed: 32022611
Li H, Zhang X, Xu H, et al. Long-term outcomes of interventional treatment for Budd-Chiari syndrome with chronic accessory hepatic vein obstruction. Eur J Gastroenterol Hepatol. 2021;33:709–16.
doi: 10.1097/MEG.0000000000001784
pubmed: 32483089
Li J, Wang C, Xu W, et al. The Long-Term Effect of Accessory Hepatic Vein Interventional Recanalization on Budd-Chiari Syndrome. Lin Chuang Fang She Xue Za Zhi. 2018;37:126–30.
Liu L, Hou G, Zhang T. Effects of patent accessory hepatic vein in the treatment of Budd-Chiari syndrome with hepatic vein occlusion. Chin J Gen Surg. 2021;36:512–5.
Lv LL, Zhu LL, Chen GH, et al. Recanalization of accessory hepatic vein for hepatic vein-type Budd-Chiari syndrome. Abdom Radiol (NY). 2021;46:3456–63.
doi: 10.1007/s00261-021-02977-1
pubmed: 33630127
Qi Z, Zhang Q, Xu H, et al. Accessory hepatic vein stenting to treat primary Budd-Chiari syndrome. Chin J Hepatobiliary Surg. 2017;23:655–8.
Wang W, Wei N, Fu Y, et al. Application of percutaneous transluminal angioplasty of accessory hepatic vein in management of Budd Chiari syndrome secondary to segmental hepatic venous obstruction. Lin Chuang Fang She Xue Za Zhi. 2015;34:1293–7.
Xia FF, Ni CF, Zu MH. Percutaneous recanalization in hepatic vein-type Budd-Chiari syndrome: hepatic or accessory hepatic vein. Minim Invasive Ther Allied Technol. 2022. https://doi.org/10.1080/13645706.2022.2145568 .
doi: 10.1080/13645706.2022.2145568
pubmed: 36398905
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
doi: 10.1001/jama.283.15.2008
pubmed: 10789670
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
doi: 10.1007/s10654-010-9491-z
pubmed: 20652370
Lu L, Xu K, Han C, et al. Comparison of 3.0T MRI with 3D LAVA sequence and digital subtraction angiography for the assessment of accessory hepatic veins in Budd-Chiari syndrome. J Magn Reson Imaging. 2017;45:401–9.
doi: 10.1002/jmri.25381
pubmed: 27388772
Cai SF, Gai YH, Ma S, et al. Ultrasonographic visualization of accessory hepatic veins and their lesions in Budd-Chiari syndrome. Ultrasound Med Biol. 2015;41:2091–8.
doi: 10.1016/j.ultrasmedbio.2015.03.023
pubmed: 25952161
Valla DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction. Hepatol Int. 2018;12:168–80.
doi: 10.1007/s12072-017-9810-5
pubmed: 28685257
Iliescu L, Toma L, Mercan-Stanciu A, et al. Budd-Chiari syndrome - various etiologies and imagistic findings. A pictorial review. Med Ultrason. 2019;21:344–8.
doi: 10.11152/mu-1921
pubmed: 31476215
Han G, Qi X, Zhang W, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013;266:657–67.
doi: 10.1148/radiol.12120856
pubmed: 23143028